Blocknomi
Key Takeaways Gilead Sciences shares have appreciated approximately 35% year-over-year, with recent trading activity near $147.82. Biktarvy, the company’s leading HIV therapy, plus emerging prophylactic treatment Yeztugo are powering robust…
Related articles
-
PropAMMs lower Solana trade costs, and public pool returns crash
CryptoSlate Published 02.10.2026 03:50
-
Bitcoin Price Analysis: Is BTC Running Out of Steam After Another Rejection at $87K?
CryptoPotato Published 05.10.2026 16:12
-
Deutsche Bank To Debut Bitcoin Custody Within Weeks: Report
Bitcoin Magazine Published 16.10.2026 16:35
-
STRK Surges 25% as Starknet Votes on Ethereum 'Divorce' for Quantum Security
U.Today Published 15.10.2026 12:25
-
Ethereum Price Prediction: Hyperliquid Whale Opens $60M ETH Long
Cryptonews Published 13.10.2026 12:11
-
CME Targets October 19 Start For Bitcoin Cash And Uniswap Futures
NewsBTC Published 19.10.2026 18:00
-
Sam Altman's World Takes Proof-of-Human IDs to Banks, Citing $40B AI Fraud Risk
Decrypt Published 19.10.2026 11:40
-
Polymarket Token Airdrop? TOKEN2049 Talk Fuels Speculation
Cryptonews Published 14.10.2026 07:27